Acorda completes enrollment in trial of Fampridine-SR for multiple sclerosis

By Lisa Kerner

Erie, Pa., March 3 - Acorda Therapeutics, Inc. said it completed enrollment in its phase 3 clinical trial of Fampridine-SR, which will evaluate the safety and efficacy of the drug in improving walking ability in people with multiple sclerosis.

The primary endpoint of the study is improvement in walking ability, and the secondary endpoints are measured leg strength and muscle spasticity, according to a company news release.

Trial data is expected in the third quarter of 2006.

Acorda also expanded its sales force for Zanaflex Capsules (tizanidine hydrochloride), for the management of spasticity, to 32 from 14 people and will continue to focus on the neurology and physical medicine and rehabilitation markets.

Acorda is a commercial-stage biopharmaceutical company based in Hawthorne, N.Y., that develops and commercializes novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.